AsclepiX Therapeutics LLC represents the next generation of biologics and drug development technology. We use bioinformatics and systems biology methods to design classes of short biomimetic anti-angiogenic (anti-neovascular) and anti-lymphangiogenic peptides, and we use the latest developments in biomaterials and drug delivery to design long-lasting biodegradable nano- and microparticles to deliver these biomimetic therapeutic peptides throughout the body. We are utilizing our platform technology for indications in ophthalmology, oncology, and for other angiogenesis- and lymphangiogenesis-dependent diseases. We are initially targeting Macular Edema, Neovascular Age-Related Macular Degeneration (wet AMD), and solid tumors with other applications to follow.

AsclepiX Therapeutics LLC is based in Baltimore, Maryland and is part of the Johns Hopkins FastForward Accelerator. It was founded by Drs. Jordan J. Green and Aleksander S. Popel based on the technologies they developed at the Johns Hopkins University School of Medicine.